Shots:
- The companies collaborated to evaluate ADG106 + Keytruda in dose-escalation and expansion clinical study to treat advanced or metastatic solid tumors & hematological malignancies
- In preclinical studies, ADG106 showed antitumor activity and was well tolerated as a monothx. and in combination with other immuno-oncology therapies
- ADG106 is a fully human, ligand-blocking, agonistic anti-CD137 IgG4 mAb engineered using its NEObody platform technology & is being evaluated in a P-Ib/II combination study for advanced solid tumors and r/r NHL, based on the P-I data
Click here to read full press release/ article | Ref: Globe Newswire | Image: Adagene
The post Merck Enters in Third Clinical Trial Collaboration with Adagene to Advance ADG106 + Keytruda (pembrolizumab) for Solid Tumors and Hematological Malignancies first appeared on PharmaShots.
